Navigation Links
Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
Date:8/29/2007

SOUTH SAN FRANCISCO, Calif., Aug. 29 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that it will hold a webcast briefing for analysts and investors in conjunction with the International Association for the Study of Lung Cancer's (IASLC) 12th World Conference on Lung Cancer. The webcast will be held on Wednesday, September 5, 2007, at 5:00 a.m. PDT/8:00 a.m. EDT. During the webcast, Exelixis management will discuss data from a Phase 2 trial of XL647 in non-small cell lung cancer patients presented at the Conference.

The webcast may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

An archive of this webcast will be available until 8:59 p.m. PDT/11:59 p.m. EDT on October 5, 2007. Access numbers for this replay are 888-286-8010 (domestic) and 617-801-6888 (international). The replay passcode is 18807116.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site a
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) ... 2014 ended July 31, 2014 on Monday, September 29 before ... the results at 11:00 AM ET. Participating in the call ... A. Krakauer , President and CEO; Jorgen B. Hansen ... , Senior Vice President, CFO and Treasurer; and Seth ...
(Date:9/22/2014)...  For many people experiencing issues with their ... prospect of large, painful incisions and long recovery ... also impacted, such as working, driving and even ... some patients even delay necessary treatment, resorting to ... permanent damage for some conditions. Logo ...
(Date:9/22/2014)... PLYMOUTH MEETING, Pa. , Sept. 22, 2014 ... ) announced today it has initiated a phase ... The trial will evaluate the safety, tolerability, and ... type 6 (HPV-6), which causes most aerodigestive cancers. ... tongue, nose, throat, vocal cords, and parts of ...
Breaking Medicine Technology:Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2Phoenix Arizona Hand Doctor Develops Revolutionary New Surgery System, Eliminates Need for Large Incisions 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4
... SPRING, Md., March 11 In a boost to,HIV ... provide a,royalty-free license to the non-profit International Partnership for,Microbicides ... as a,potential vaginal microbicide., The compound, called L,644, ... as gp41 fusion inhibitors, which inhibit HIV infection by,preventing ...
... data provides evidence for, potential benefit of starting Femara up to seven years after ... tamoxifen, ... published in Journal of Clinical Oncology, - Half of all breast cancer recurrences occur ... ...
Cached Medicine Technology:Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc. 2Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc. 3VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy 2VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy 3VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy 4VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy 5VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy 6VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy 7
(Date:9/22/2014)... Austin, Texas (PRWEB) September 22, 2014 ... testing and treatment, will work with companies to help ... prevent the development of diabetes as part of a ... Stop Diabetes @ Work initiative. , PreDiabetes Centers ... Texas Department of Transportation in Austin on Tuesday, October ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... that bacterial pneumonia can raise your risk of heart problems, ... and kill heart cells, increasing the chances of heart failure, ... report. In mice, monkeys and human heart tissue, researchers ... and they tried a vaccine that might one day prevent ...
(Date:9/22/2014)... At the 10th Clinton Global ... Partnership (SNP) announced the successful launch of a ... Risk Reduction Program for Women. The announcement of ... their risk of heart disease through a seafood-rich ... for addressing significant global challenges made by CGI ...
(Date:9/22/2014)... Burbank, CA (PRWEB) September 22, 2014 ... social and mobile recruiting, announced today an ... talent management solutions for the healthcare industry. ... to TweetMyJobs’ suite of social recruiting solutions ... management software designed specifically for healthcare organizations. ...
(Date:9/22/2014)... -- In a collaboration that will encompass a ... and patient care and accelerate personalized genomic medicine, ... Medical Center (BIDMC) have established a new academic, ... today. , A recently signed agreement calls for ... a comprehensive relationship in the areas of research ...
Breaking Medicine News(10 mins):Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 2Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 3Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 2Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 2Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 4Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 2Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 3Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 4Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 2Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 3
... , TUESDAY, Aug. 9 (HealthDay News) -- Motion ... changing the way cars take curves, researchers say. They ... tilt only at the beginning and end of curves rather ... motion sickness. "This is a major breakthrough and a ...
... BOSTON Beth Israel Deaconess Medical Center (BIDMC) researchers ... been awarded Challenge Awards of $1 million each from ... teams of investigators in their pursuit of new treatments ... Awards will support a total of 10 scientific projects ...
... Concern about the capacity of individuals with schizophrenia to ... impairment due to psychotic symptoms associated with the disorder. ... that prospective participants make when undergoing a formal assessment ... in IRB: Ethics & Human Research ...
... 221.10.254.64 COLUMBIA, Mo. Due to changing guidelines ... screened for breast cancer with mammograms, many women are ... and older get a mammogram every year, but the ... year for women older than 50. A University of ...
... By Kathleen Doheny HealthDay Reporter , MONDAY, ... as a healthier alternative to estrogen for maintaining bone ... according to a new study. , "Our study shows ... not prevent bone loss or alleviate menopausal symptoms," said ...
... As parents prepare to send their children back to school, ... in academic performance, an expert advises. Studies have shown ... more alert throughout the school day and also earn higher ... Pat Alfaro, clinical manager of the division of nutrition therapy ...
Cached Medicine News:Health News:Going Full-Tilt Into Turns May Ease Motion Sickness on Trains 2Health News:BIDMC scientists receive Challenge Awards from Prostate Cancer Foundation 2Health News:Schizophrenia study finds cognitive deficits significantly impair decision-making capacity 2Health News:Doctors, women should spend more time discussing mammograms 2Health News:Soy Supplements Don't Ease Bone Loss, Menopausal Symptoms: Study 2Health News:Soy Supplements Don't Ease Bone Loss, Menopausal Symptoms: Study 3Health News:Healthy Lunch and Breakfast Keep Students Alert 2
... Aprons are the result of a technologically ... x-ray aprons. Constructed with a wear resistant, ... the Lead Free aprons exhibit the same ... Each apron weighs approximately 50% less than ...
... Pre-sterilized Medtronic Electrodes are made ... Polytetrafluoretylene. The exposed tip of ... and serves as the recording ... are available. Each needle is ...
... Cadwell Easy II is an advanced multi-modality ... a complete package that includes our 32-channel ... pair connectors for recording channels like airflow, ... a DC amplifier with four DC inputs, ...
... II EEG system is a fully digital 32-channel ... any practice or hospital need. It can be ... a laptop computer for out-of-lab data collection, or ... custom designed carts that will hold a high ...
Medicine Products: